Gland Pharma has received US Food and Drug Administration approval for its ready-to-use (RTU) Vasopressin Injection in 5 percent dextrose. The approval covers 40 Units/100 mL (0.4 Units/mL) vials fully authorised and 20 Units/100 mL (0.2 Units/mL) vials granted tentative approval. 

The product is bioequivalent and therapeutically equivalent to the reference drug Vasostrict, which is indicated for adults with vasodilatory shock who remain hypotensive despite adequate fluid resuscitation and catecholamine support.

According to IQVIA data, Vasostrict achieved approximately USD 45 million in US sales during the 12 months ending June 2025. This regulatory approval further strengthens Gland Pharma’s growing injectable portfolio and expands access to a critical therapy for hypotensive emergencies in intensive care settings.